🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease

Recruitingn/aAges any - anyAllPeking Union Medical College Hospital
NCT05330923 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Acquired immunodeficiency syndrome (AIDS) remains a severe global infectious disease, with over 38 million people living with HIV and around 35 million cumulative deaths worldwide by 2023; approximately 1.24 million HIV-positive individuals and 100,000 new infections are reported annually in China. Widespread use of HAART has prolonged HIV patients' survival and reduced AIDS-related mortality, yet non-AIDS comorbidities dominated by chronic liver disorders, particularly metabolic dysfunction-associated fatty liver disease (MAFLD), have become a major challenge in long-term HIV management. Triggered by elevated blood lipids from lifestyle, antiretroviral agents and inherited metabolic factors, MAFLD initiates with hepatic steatosis and may progress to NASH, liver fibrosis, cirrhosis and even hepatocellular carcinoma (HCC) without timely intervention. HIV-positive patients develop more sev

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Newly treated or treated AIDS patients; * Regular follow-up visits to the hospital, medication compliance is good; * Patients or their family members were willing to participate in the study by understanding the study plan and providing written informed consent. Exclusion Criteria: * Unable to complete the position requirements of ultrasonic examination (lying flat) due to mobility difficulties; * Patients have poor compliance and cannot follow up regularly or take medicine on time; * Patients or family members cannot understand the conditions and objectives of the study; * Other conditions considered unsuitable for inclusion by the investigator.
💊

What it tests

  • Liver Quantitative Ultrasound
📍

Where

1 site
Chinese Academy of Medical Sciences Peking Union Medical College Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy